

C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
193
Neumol Pediatr 2015; 10 (4): 189 - 193
BCG 1948 – 2014: ¿La misma cepa?
División de Control de Gestión [Internet]. Final, Informe
Inmunizaciones, Programa Nacional D E Salud, Ministerio
D E. 2012. Available from:
http://www.dipres.gob.cl/574/articles-89691_doc_pdf.pdf
6. Nacional P, Transmisibles E. TUBERCULOSIS. 2014;
Available from:
http://epi.minsal.cl/epi/html/bolets/reportes/tuberculosis/informe_tuberculosis.pdf
7. 7.
Brennan MJ, Thole J. Tuberculosis vaccines: A
strategic blueprint for the next decade. Tuberculosis (Edinb).
2012;92 Suppl 1:S6-13
8. Barreto ML, Pilger D, Pereira SM, Genser B, Cruz A , Cunha
SS et al. Causes of variation in BCG vaccine efficacy:
examining evidence from the BCG REVAC cluster randomized
trial to explore the masking and the blocking hypotheses.
2014 Jun 24;32:3759-64
9. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J,
et al. The second Geneva Consensus: Recommendations for
novel live TB vaccines. Vaccine. 2010;28:2259–70
10. Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE,
Torres M. Human immunity to M. tuberculosis: T cell subsets
and antigen processing. Tuberculosis 2003;83:98–103
11. Gowthaman U, Mushtaq K, Tan AC, Rai PK, Jackson DC,
Agrewala JN. Challenges and solutions for a rational
vaccine design for TB-endemic regions. Crit Rev Microbiol
2014;7828:1–10
12. Jensen, KJ; Larsen N, Biering-Sørensen S, Andersen A,
Eriksen HB, Monteiro I, Hougaard D, Aaby P, Netea MG,
Flanagan KL, Benn CS. Heterologous Immunological Effects
of Early BCG Vaccination in Low-Birth-Weight Infants in
Guinea-Bissau: A Randomized-controlled Trial. J Infect Dis.
2015;211:956–67
13. Clothier HJ1, Hosking L, Crawford NW, Russell M, Easton
ML, Quinn JA, Buttery JP. Bacillus Calmette-Guérin ( BCG
) Vaccine Adverse Events in Victoria , Australia : Analysis of
Reports to an Enhanced Passive Surveillance System . Drug
Saf 2015;38:79–86
14. Lakhar BB, Neonatal BCG and scar success. Indian Pediatr
1995;32:1323
15. 15. Ritz N, Tebruegge M, Camacho-Badilla K, Haeusler
GM, Connell TG, Curtis N. To TST or not to TST: is tuberculin
skin testing necessary before BCG immunisation in children?
Vaccine 2012;14:1434–6
16. Sayyahfar S, Karimi A, Fahimzad A, Shamshiri AR. Comparison
of Tuberculin Skin Test result and interferon gamma response
to human PPD in BCG scar positive and negative children. J
Epidemiol Glob Health 2014;4:45–50
17. Biering-Sørensen S, Jensen KJ, Aamand SH, Blok B, Andersen
A, Monteiro I et al. Variation of growth in the production
of the BCG vaccine and the association with the immune
response. An observational study within a randomised trial.
Vaccine 2015;33:2056-65
18. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine
PEM et al. Protection by BCG vaccine against tuberculosis: a
systematic review of randomized controlled trials. Clin Infect
Dis 2014 ;58:470–80
19. Ortqvist Å, Blennow M, Carlsson R-M, Hanson LÅ, Lindberg
a, Lindqvist L et al. Vaccination of children--a systematic
review. Acta Paediatr Suppl 2010;99:1–192
20. Fifteen year follow up of trial of BCG vaccines in south India
for tuberculosis prevention. Tuberculosis Research Centre
(ICMR), Chennai. [No authors listed].Indian J Med Res
1999;110:56-69
21. Hart D’Arcy P, Sutherland I. BCG and vole bacillus vaccines
in the prevention of tuberculosis in adolescence and early
adult life. Final report to the Medical Research Council. Br
Med J 1977;2:293–5
22. Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy.
A methodological and statistical reappraisal. JAMA. 1983
May 6;249:2362-9
23. Wilson ME, Fineberg H V, Colditz GA. Geographic latitude and
the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect
Dis 1995;20:982–91
24. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME,
Burdick E, Fineberg HV. The efficacy of bacillus Calmette-
Guérin vaccination of newborns and infants in the prevention
of tuberculosis: meta-analyses of the published literature.
Pediatr1995;96:29–35
25. Subsecretaria de Salud Pública. Ordinario B27/N 2574
Lineaminetos de vacunación frente a situaciones especiales
26. Al-Kassimi FA, Al-Hajjaj MS, Al-Orainey IO, Bamgboye EA.
Does the protective effect of neonatal BCG correlate with
vaccine-induced tuberculin reaction? Am J Respir Crit Care
Med 1995;152:1575–8
27. Citron KM, Lunn JA. Immunisation against infectious disease.
BMJ 1998;297:1406
28. Toukam Tchakoute C, Hesseling AC, Kidzeru EB, Gamieldien
H, Passmore J-AS, Jones CE et al. Delaying BCG vaccination
until 8 weeks of age results in robust BCG-specific
T cell responses in HIV-exposed infants. J Infect Dis
2015;211:338-46
29. Karp CL, Wilson CB, Stuart LM, Bill T, Foundation MG.
Tuberculosis vaccines : barriers and prospects on the quest
for a transformative tool. Immunol Rev 2015;363–81
30. Rodrigues LC, Mangtani P, Abubakar I. How does the level of
BCG vaccine protection against tuberculosis fall over time?
BMJ 2011;343:d5974